Skip to main content
Top
Published in: Endocrine 2/2009

01-10-2009 | Original Paper

Improving insulin resistance with traditional Chinese medicine in type 2 diabetic patients

Authors: Menglei Chao, Dajin Zou, Yifei Zhang, Yuhong Chen, Miao Wang, Hong Wu, Guang Ning, Weiqing Wang

Published in: Endocrine | Issue 2/2009

Login to get access

Abstract

Some clinical studies and animal researches have evaluated the efficacy of Traditional Chinese Medicine (TCM) and compared its effects with placebo or other antidiabetic drugs. TCM involves three particular plants, as an antidiabetic drug. Our present research planned to evaluate the efficacy of TCM on insulin sensitivity and other related metabolic factors in type 2 diabetic patients. There were 43 newly diagnosed type 2 diabetic patients enrolled in this study, who did not use any antidiabetic drugs before. They were randomly assigned into TCM and placebo groups, administrated with TCM and placebo, respectively. Glucose disposal rate, fasting plasma glucose, postprandial plasma glucose, glycated hemoglobin, and other metabolic components were assessed at baseline and end point. Glucose disposal rate increased from 5.12 ± 2.20 to 6.37 ± 3.51 mg kg−1 min−1 in the TCM group, ANCOVA analysis showed that glucose disposal rate in the TCM group was significantly improved as compared to that in the placebo group (P < 0.05). Other metabolic related components such as fasting plasma glucose, postprandial plasma glucose, glycated hemoglobin, systolic blood pressure, diastolic blood pressure, body mass index, retinol binding protein 4 were improved in TCM group, but no statistical differences was detected between the two groups. No severe side effect was found in TCM group. TCM can ameliorate insulin resistance in type 2 diabetes and it is safe and effective in newly diagnosed diabetic patients.
Literature
1.
go back to reference International Diabetes Federation, Diabetes Atlas, 3rd edn. (International Diabetes Federation, Brussels, 2006) International Diabetes Federation, Diabetes Atlas, 3rd edn. (International Diabetes Federation, Brussels, 2006)
2.
go back to reference E.S. Ford, Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome. Diabetes Care 28, 1769–1778 (2005)CrossRefPubMed E.S. Ford, Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome. Diabetes Care 28, 1769–1778 (2005)CrossRefPubMed
3.
go back to reference G. Ravaglia, P. Forti, F. Maioli, Metabolic syndrome: prevalence and prediction of mortality in elderly individuals. Diabetes Care 9, 2471–2476 (2006)CrossRef G. Ravaglia, P. Forti, F. Maioli, Metabolic syndrome: prevalence and prediction of mortality in elderly individuals. Diabetes Care 9, 2471–2476 (2006)CrossRef
4.
go back to reference N. Qing, C. Shi-bo, Z. Xue-zhong, Analysis on characteristics of the complication of metabolic syndrome in type 2 diabetes patients. J. Tradit. Chin. Med. 9, 809–811 (2007). [article in Chinese] N. Qing, C. Shi-bo, Z. Xue-zhong, Analysis on characteristics of the complication of metabolic syndrome in type 2 diabetes patients. J. Tradit. Chin. Med. 9, 809–811 (2007). [article in Chinese]
5.
go back to reference L. Ji-lin, The herbalism analysis of berberine on diabetes. J. Sichuan Tradit. Med. 11, 17–19 (1999). [article in Chinese] L. Ji-lin, The herbalism analysis of berberine on diabetes. J. Sichuan Tradit. Med. 11, 17–19 (1999). [article in Chinese]
6.
go back to reference S. Zhu-fang, X. Ming-zhi, L. Hai-fan, The effect of Jinqi tablet on glucose metabolism in experimental animals. Tradit. Chin. Drug Res. Clin. Pharmacol. 7, 24–26 (1996). [article in Chinese] S. Zhu-fang, X. Ming-zhi, L. Hai-fan, The effect of Jinqi tablet on glucose metabolism in experimental animals. Tradit. Chin. Drug Res. Clin. Pharmacol. 7, 24–26 (1996). [article in Chinese]
7.
go back to reference S. Zhu-fang, X. Ming-zhi, L. Hai-fan, The effects of Jinqi tablets on lipid, insulin resistance and immunologic function in experimental animals. Tradit. Chin. Drug Res. Clin. Pharmacol. 8, 23–25 (1997). [article in Chinese] S. Zhu-fang, X. Ming-zhi, L. Hai-fan, The effects of Jinqi tablets on lipid, insulin resistance and immunologic function in experimental animals. Tradit. Chin. Drug Res. Clin. Pharmacol. 8, 23–25 (1997). [article in Chinese]
9.
go back to reference K.G. Alberti, P.Z. Zimmet, Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 15(53), 9–553 (1998) K.G. Alberti, P.Z. Zimmet, Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 15(53), 9–553 (1998)
10.
go back to reference Y.F. Zhang, J. Hong, W.W. Zhan, Elevated serum level of interleukin-18 is associated with insulin resistance in women with polycystic ovary syndrome. Endocrine 29, 419–423 (2006)CrossRefPubMed Y.F. Zhang, J. Hong, W.W. Zhan, Elevated serum level of interleukin-18 is associated with insulin resistance in women with polycystic ovary syndrome. Endocrine 29, 419–423 (2006)CrossRefPubMed
11.
go back to reference R.A. Defronzo, J.D. Tobin, R. Andres, Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237, E214–E223 (1979)PubMed R.A. Defronzo, J.D. Tobin, R. Andres, Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237, E214–E223 (1979)PubMed
12.
go back to reference S. Soonthornpun, W. Setasuban, A. Thamprasit, Novel insulin sensitivity index derived from oral glucose tolerance test. J. Clin. Endocrinol. Metab. 88, 1019–1023 (2003)CrossRefPubMed S. Soonthornpun, W. Setasuban, A. Thamprasit, Novel insulin sensitivity index derived from oral glucose tolerance test. J. Clin. Endocrinol. Metab. 88, 1019–1023 (2003)CrossRefPubMed
13.
go back to reference Y. Zhang, X. Li, D. Zou, Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J. Clin. Endocrinol. Metab. 93, 2559–2565 (2008)CrossRefPubMed Y. Zhang, X. Li, D. Zou, Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J. Clin. Endocrinol. Metab. 93, 2559–2565 (2008)CrossRefPubMed
14.
go back to reference W. Kong, J. Wei, P. Abidi, Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat. Med. 10, 1344–1351 (2004)CrossRefPubMed W. Kong, J. Wei, P. Abidi, Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat. Med. 10, 1344–1351 (2004)CrossRefPubMed
15.
go back to reference Y.S. Lee, W.S. Kim, K.H. Kim, Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistance states. Diabetes 55, 2256–2264 (2006)CrossRefPubMed Y.S. Lee, W.S. Kim, K.H. Kim, Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistance states. Diabetes 55, 2256–2264 (2006)CrossRefPubMed
16.
go back to reference N. Turner, J.Y. Li, A. Gosby, Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes 57, 1414–1418 (2008)CrossRefPubMed N. Turner, J.Y. Li, A. Gosby, Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes 57, 1414–1418 (2008)CrossRefPubMed
17.
go back to reference J. Yin, R. Hu, M. Chen, Effects of berberine on glucose metabolism in vitro. Metabolism 51, 1439–1443 (2002)CrossRefPubMed J. Yin, R. Hu, M. Chen, Effects of berberine on glucose metabolism in vitro. Metabolism 51, 1439–1443 (2002)CrossRefPubMed
18.
go back to reference L. Zhou, Y. Yang, X. Wang, Berberine stimulates glucose transport through a mechanism distinct from insulin. Metabolism 56, 405–412 (2007)CrossRefPubMed L. Zhou, Y. Yang, X. Wang, Berberine stimulates glucose transport through a mechanism distinct from insulin. Metabolism 56, 405–412 (2007)CrossRefPubMed
19.
go back to reference G.Y. Pan, Z.J. Huang, G.J. Wang, The antihyperglycaemic activity of berberine arises from a decrease of glucose absorption. Planta Med. 69, 632–636 (2003)CrossRefPubMed G.Y. Pan, Z.J. Huang, G.J. Wang, The antihyperglycaemic activity of berberine arises from a decrease of glucose absorption. Planta Med. 69, 632–636 (2003)CrossRefPubMed
20.
go back to reference T.E. Graham, Q. Yang, M. Bluher, Retimol-binding protein 4 and insulin resistance in lean, obese and diabetic subjects. N. Engl. J. Med. 354, 2552–2563 (2006)CrossRefPubMed T.E. Graham, Q. Yang, M. Bluher, Retimol-binding protein 4 and insulin resistance in lean, obese and diabetic subjects. N. Engl. J. Med. 354, 2552–2563 (2006)CrossRefPubMed
Metadata
Title
Improving insulin resistance with traditional Chinese medicine in type 2 diabetic patients
Authors
Menglei Chao
Dajin Zou
Yifei Zhang
Yuhong Chen
Miao Wang
Hong Wu
Guang Ning
Weiqing Wang
Publication date
01-10-2009
Publisher
Springer US
Published in
Endocrine / Issue 2/2009
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-009-9222-y

Other articles of this Issue 2/2009

Endocrine 2/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.